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Abstract: Triamcinolone acetonide (TA) is a corticosteroid that has many uses in the treatment 
of ocular diseases because of its potent anti-inﬂ  ammatory and anti-permeability actions. 
Intraocular inﬂ  ammation broadly referred to as uveitis can result from several causes, including 
the immune system and after ophthalmic surgery. One of the most common reasons for vision 
loss with uveitis is macular edema. TA has been used for many years as an intravitreal injection 
for the treatment of ocular diseases. Several case control studies have been reported showing the 
efﬁ  cacy of TA in the treatment of intraocular inﬂ  ammation and associated macular edema caused 
by Behcet’s disease, Vogt-Koyanagi-Harada syndrome, sympathetic ophthalmia and white dot 
syndromes. It has also been shown efﬁ  cacious in cases of pars planitis and idiopathic posterior 
uveitis. Some authors have reported its use in postoperative cystoid macular edema. Many of 
the studies on the use of TA in controlling intraocular inﬂ  ammation and concomitant macular 
edema showed its effect to be transient in many patients requiring reinjection. Complications 
can arise from intravitreal injection of TA including elevated intraocular pressure and cataract. 
Rarely, it can be associated with infectious and non-infectious endophthalmitis. TA may be 
useful as an adjuvant in the treatment of uveitis and its associated macular edema, especially 
in patients resistant or intolerant to standard treatment.
Keywords: triamcinolone acetonide, Behcet’s disease, sympathetic ophthalmia, 
Vogt-Koyanagi-Harada syndrome, white dot syndromes, uveitis, cataract surgery, macular 
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Triamcinolone acetonide (TA) is a water-insoluble corticosteroid that is used 
extensively in many ﬁ  elds of medicine, including ophthalmology. It can be admin-
istered multiple ways for ocular disease, including injection under Tenon’s capsule, 
into the retrobulbar space or directly into the vitreous. TA has been advocated for both 
medical and surgical diseases of the eye. Its use as an intravitreal injection was ﬁ  rst 
made popular by Machemer in an attempt to prevent cellular proliferation after retinal 
detachment surgery.1 Throughout decades of use, intravitreal TA has been adopted for 
many indications, including uveitis, vasculitis, proliferative vitreoretinopathy, macular 
degeneration and a number of causes for macular edema.2,3,4,5,6,7
Corticosteroids are well known anti-inﬂ  ammatory agents used in many facets of 
medicine. They inhibit phospholipase A2 induction through lipocortin production.8,9 
Corticosteroids have also been shown to downregulate many inflammatory 
mediators including multiple interleukins, prostaglandins and tumor necrosis fac-
tor.10,11 In addition to dampening the inﬂ  ammatory response, corticosteroids have 
anti-angiogenic, vasoconstrictive and anti-permeability effects.12,13,14 Within the 
eye, corticosteroids help maintain the blood-retinal barrier and facilitate reabsorp-
tion of exudates.15 TA is a synthetic corticosteroid that is ﬁ  ve times more potent 
than equivalent doses of prednisone.16 TA speciﬁ  cally has been shown to have 
profound anti-angiogenic effects.17 TA has gained favor in ophthalmology because Clinical Ophthalmology 2009:3 42
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its relatively small particles can be injected in or around the 
eye and its duration of action is several months.
TA for ophthalmic use can be prepared and administered 
in multiple ways. The suspension can be injected subcon-
junctivally, into the subtenons space or as a retrobulbar 
injection. However, variable intraocular concentrations of 
TA are obtained since the diffusion of the particles is limited 
by Tenon’s capsule and the sclera. To obtain predictable 
intraocular concentrations, direct treatment of intraocular 
inﬂ  ammation can be achieved through intravitreal injections. 
Several formulations are available for intraocular injection. 
Trisence® (Alcon, Fort Worth, TX, USA) is a commercially 
available preservative-free preparation of TA that is FDA 
approved for intraocular use. The concentration of TA is 
40 mg/mL and recommended dosing is 1–4 mg (25–100 μL). 
Trivaris® (Allergan, Irvine, CA, USA) is another commer-
cially available preservative-free TA preparation available as 
a single use syringe for intravitreal injection. Instead of a sus-
pension, Trivaris® is a gel preparation and has a concentration 
of 80 mg/mL. Finally, Kenalog® (Bristol-Myers Squibb, 
Peapack, NJ, USA) is available for use off-label. It can be 
used in its provided form, but many retinal specialists prefer 
that the preservative is removed by a compounding pharmacy 
prior to administration.
Uveitis is a broad term used to describe intraocular 
inﬂ  ammation speciﬁ  cally within the iris, ciliary body or 
choroid. Uveitis can be classiﬁ  ed many different ways. 
Anterior uveitis implies inﬂ  ammation in the iris or anterior 
ciliary body, intermediate uveitis describes inﬂ  ammation 
in the posterior ciliary body and associated retina, and 
inﬂ  ammation in the choroid is described as posterior uveitis. 
Causes of this complex inﬂ  ammatory cascade can include 
infectious, traumatic, immune-mediated or surgically 
induced. Intraocular inﬂ  ammation can lead to vision loss 
through many mechanisms including retinal inﬂ  ammation, 
optic nerve inﬂ  ammation and macular edema. One of the 
responses to inﬂ  ammation within the macula is accumulation 
of ﬂ  uid within the loosely woven ﬁ  bers of Henle in the 
outer plexiform layer. This response, called cystoid macular 
edema, is the most common reason for vision loss with 
uveitis. Anti-inﬂ  ammatories, speciﬁ  cally corticosteroids, 
are the cornerstone of treatment for uveitis and associated 
macular edema. Local therapy with topical drops or injec-
tions into the subconjunctival, subtenon’s and retrobulbar 
spaces are used as treatment options; however, intraocular 
levels are variable. Systemic immunosuppressives, including 
corticosteroids, are important in the treatment of severe 
uveitis. For inﬂ  ammation involving the posterior segment, 
direct treatment via intravitreal injections of corticosteroids 
can be used in an attempt to achieve desired predictable 
intraocular concentrations.
Autoimmune uveitis
Autoimmune uveitis, like other forms of autoimmune disease, 
is thought to occur through a breakdown in immunologic 
self-regulation. Complex immunologic events are involved 
in the development and progression of autoimmune uveitis. 
The location and pattern of inﬂ  ammation may lead to a 
diagnosis; however, often the cause of autoimmune uveitis 
cannot be discovered. The causes of this inﬂ  ammation can 
be isolated to the eye or may be part of a larger systemic 
disease. Isolated causes of uveitis include pars planitis, 
white dot syndromes, sympathetic ophthalmia and acute 
retinal necrosis. Often uveitis is a manifestation of systemic 
diseases including sarcoidosis, juvenile rheumatoid arthritis, 
inﬂ  ammatory bowel disease, systemic lupus erythematosus, 
Behcet’s disease (BD), Vogt-Koyanagi-Harada syndrome 
(VKH) and multiple sclerosis. The preferred treatment of 
uveitis depends on the location and severity of inﬂ  amma-
tion and presence of vision loss. As described previously, 
the most common cause of vision loss with uveitis is cystoid 
macular edema.
BD describes an idiopathic systemic inﬂ  ammatory condi-
tion with a classic triad of uveitis, aphthous stomatitis and 
genital ulcers. Severe relapsing panuveitis and profound 
vision loss are common ocular manifestations. Systemic 
immunosuppressives are critical in the treatment of BD. 
Patients who are intolerant of systemic therapy or those 
whose intraocular inﬂ  ammation is refractory to treatment 
may require eye targeted therapy. Several studies have 
advocated the use of intravitreal TA in the treatment of 
patients with BD who have refractory panuveitis with vision 
loss.18,19,20,21,22 In the study by Tuncer et al all of the patients 
given intravitreal TA had resolution of intraocular inﬂ  am-
mation and improvement of visual acuity.19 Only one fourth 
of the patients had relapsing inﬂ  ammation within 2 years of 
injection. Associated macular edema was shown to decrease 
in over 80% of patients described in several studies.20,21 
Oghuro et al suggests that repeat intraocular TA injections 
may prevent recurrent attacks of uveitis with BD.22 These 
studies have illustrated intravitreal TA’s use in refractory 
panuveitis associated with BD.
Sympathetic ophthalmia (SO) describes a potentially 
severe, vision-threatening immune-mediated panuveitis 
following penetrating trauma to the fellow eye. This is 
a potentially severe consequence of a penetrating ocular Clinical Ophthalmology 2009:3 43
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injury and requires lifelong treatment. Vision loss is 
commonly secondary to serous retinal detachments and 
macular swelling. Prior to the advent of corticosteroids, this 
disease commonly led to blindness. Traditionally, systemic 
immunosuppressives, including corticosteroids, are the 
mainstay of treatment for SO. Multiple routes of adminis-
tration for corticosteroids coupled with early recognition 
and treatment have improved the prognosis for this disease. 
Several case reports illustrate favorable results with the use 
of intravitreal TA as treatment for both acute and chronic 
SO.23,24,25,26 Two cases reported of acute SO with associated 
serous retinal detachments, retinal edema and vision loss 
were treated with intravitreal TA. The vision dramatically 
improved and the retinal swelling signiﬁ  cantly improved 
within two weeks of treatment. The patients were clinically in 
remission within 3 months of treatment.23,25 Jonas and Span-
dau describe a case of SO treated with intravitreal TA who 
also acutely improved both objectively and subjectively.24 
After over 2 years of repeated injections, the described 
patient’s vision has remained stable and her systemic immu-
nosupressives have been decreased signiﬁ  cantly.26 Because 
of the remote incidence of SO, randomized trials cannot be 
conducted; however, these cases have shown a beneﬁ  t for 
early and continued treatment with intravitreal TA.
VKH describes a rare idiopathic systemic disease of 
melanocyte-containing tissues. The cutaneous manifesta-
tions of this disease include poliosis, vitiligo and alopecia. 
Neurologic consequences include encephalitis, tinnitus and 
dysacusis. The ocular complications resemble those seen 
with SO and include granulomatous panuveitis with severe 
vision loss. Like SO, systemic immunosuppressives are 
the cornerstone of treatment. However, like other diseases 
requiring systemic immunosuppressives, adverse effects 
of treatment are common, necessitating the use of local 
therapy. Several cases of VKH treated with intravitreal TA 
have been reported with favorable results. All of the cases 
reported showed a rapid improvement in vision and clinical 
appearance with up to 14 months of stability.27,28,29 No data 
on the long-term use of intravitreal TA for VKH have been 
reported.
Immune recovery uveitis (IRU) describes rebound 
ocular inﬂ  ammation following an acute ocular inﬂ  ammatory 
syndrome in a reversibly immunocompromised patient. 
This condition became widely recognized with the begin-
ning of highly active antiretroviral therapy (HAART) for 
acquired immunodeficiency syndrome (AIDS). These 
patients would develop infectious retinitis and have a severe 
vision-threatening uveitis following treatment of the retinitis 
and initiation of HAART. It was found in one study to occur 
in up to 15% of AIDS patients following cytomegalovirus 
(CMV) uveitis.30 In addition to AIDS-associated IRU, other 
reversible causes of immune compromise including systemic 
chemotherapy and solid organ transplantation have been 
associated with IRU. Sirimaharaj et al described the use of 
intravitreal TA in two patients with HIV associated IRU. 
Both patients improved clinically and subjectively.31 One 
interventional case series of cystoid macular edema (CME) 
with IRU showed an average three-line improvement in 
visual acuity and improvement in macular edema 3 months 
following a single intravitreal TA injection.32 Because 
systemic immunosuppression allowed for the infectious 
retinitis care must be taken in treating IRU with medications 
that have systemic consequences, which would suggest the 
use of highly directed local therapy like intravitreal TA.
Multifocal areas of inﬂ  ammation within the retina and 
choroid characterized by white dots are generally classiﬁ  ed 
as white dot syndromes. The white dot syndromes then can 
be organized into separate categories depending on pattern 
and location of inflammatory lesions. These categories 
include acute posterior multifocal placoid pigment epitheli-
opathy (AMPPE), multiple evanescent white dot syndrome 
(MEWDS), birdshot chorioretinopathy, punctate inner 
choroidopathy (PIC), serpiginous choroiditis and multifocal 
choroiditis and panuveitis (MCP). The syndromes that more 
commonly manifest with severe visual loss and macular 
edema include birdshot chorioretinopathy and serpiginous 
choroiditis. They are characterized by ocular inﬂ  ammation 
that is recalcitrant and reoccurring. Most commonly these 
syndromes are treated with systemic immunosuppression; 
however additional or alternative treatment may be required. 
Serpiginous choroiditis is characterized by bilateral inﬂ  am-
mation with yellow subretinal inﬁ  ltrates extending from the 
optic disc in a geographic pattern.33 Several cases have been 
reported of rapid remission of inﬂ  ammation after intravitreal 
TA injection.34,35,36 The inﬂ  ammation has been reported to 
be decreased for up to 10 months.35 In addition, cases of 
associated macular edema rapidly resolved after TA.34,36 
Birdshot retinochoroidopathy, also called vitiliginous, is 
characterized by bilateral cream-colored lesions in the 
posterior pole. It is has a presumed autoimmune etiology as 
it is highly associated with HLA-A29. Shah and Brandley 
describe a case of birdshot retinochoroidopathy that was 
managed over a 3-year period with repeated intravitreal TA 
injections given every 10 months. This was done because the 
patient refused systemic therapy and the patient’s vision and 
clinical exam remained under control with this treatment.37 Clinical Ophthalmology 2009:3 44
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Martidis et al described two cases of CME due to birdshot 
chorioretinopathy successfully treated with intravitreal 
TA.38 While it is an uncommon manifestation of AMPPE, 
Yenerel et al describe a case of late onset AMPPE presenting 
with CME that was successfully treated with intravitreal 
TA.39 White dot syndromes are uncommon but the vision 
loss associated with them can be profound. Intravitreal TA 
can be considered in cases when inﬂ  ammation is recurrent 
despite systemic immunosuppression or the treatment is not 
tolerated.
Idiopathic uveitis
While it is important to rule out autoimmune and infectious 
causes of uveitis, often intraocular inﬂ  ammation can occur 
without an identiﬁ  able reason. This can be especially true 
for patients with intermediate uveitis but can also occur 
with posterior uveitides. Pars planitis refers to idiopathic 
intermediate uveitis. Like the other uveitides, the main cause 
of vision loss is cystoid macular edema. Despite effective 
treatment of inﬂ  ammation with systemic immunosuppres-
sives the macular edema may persist. Treatment of CME 
with idiopathic uveitis classically is with posterior sub-tenons 
(PST) deposits of steroids, but a recent study by Choudhry 
showed no difference in outcomes including recovery of 
visual acuity and angiographic resolution of macular edema 
between PST-TA and intravitreal TA.40 One case report of 
pars planitis by Degenring and Jonas illustrates effective 
resolution of CME with the use of intravitreal TA in a patient 
who was intolerant to systemic immunosuppression.41 While 
not evaluated separately, idiopathic uveitis is commonly 
evaluated in combination with other etiologies of uveitis and 
uveitic CME. A prospective case series by Ozkiris showed 
no signiﬁ  cant difference in visual outcomes and resolution 
of vitreous inﬂ  ammation between intravitreal injection of 
8 mg TA and oral corticosteroids.42 Several studies have 
been performed looking at the efﬁ  cacy of intravitreal TA in 
the treatment of uveitic CME.41,43,44,45,46,47,48,49 The dose of the 
TA used ranged from 2 mg to 4 mg injected intravitreally. 
Regardless of the dose many studies showed that intravitreal 
TA rapidly helped macular edema and consequently visual 
acuity; however, in some cases this effect appeared to be tran-
sient. Das-Bhaumik and Jones showed the efﬁ  cacy of 2 mg 
dosing of TA in causing the resolution of CME in 80% of 
patients and resolution of intraocular inﬂ  ammation in only 
half.47 Kok et al showed a statistically signiﬁ  cant improve-
ment in visual acuity in patients under 60 years old treated 
with 4 mg of intravitreal TA. The greatest improvement in 
their patients was within the ﬁ  rst 4 weeks of treatment.46 
Sorensen et al describe a relationship between efﬁ  cacy of 
intravitreal TA and etiology of uveitis. After intravitreal TA 
injection they showed resolution of CME secondary to uveitis 
and diabetic macular edema but not chronic pseudophakic 
CME.50 These studies suggest a possible role for intravitreal 
TA in helping control refractory uveitis and CME.
Postsurgical inﬂ  ammation
and macular edema
Intraocular surgery can have many complications but 
one of the more common causes of unfavorable visual 
outcomes is postoperative CME. The precise pathogenesis of 
postoperative CME is likely multifactorial and presumably 
includes inﬂ  ammation.51,52,53,54 Cataract surgery is a common 
culprit and when postoperative pseudophakic CME occurs it 
is referred to as Irvine-Gass syndrome.51 Through evolution 
of cataract surgery from extracapsular extraction to 
phacoemulsiﬁ  cation the incidence of CME has decreased.55,56 
Commonly pseudophakic CME resolves spontaneously or 
with topical treatment. Many treatments have been attempted 
for chronic nonresponsive postoperative CME including 
topical steroids, periocular deposits of steroids, topical 
nonsteroidal anti-inﬂ  ammatories, Nd:YAG vitreolysis, and 
vitrectomy.57,58,59,60,61 Several reports have been published 
showing favorable anatomic and functional outcomes after 
intravitreal TA for recalcitrant pseudophakic CME.62,63,64,65,66,67 
Koutsandrea et al showed an increase in vision and multifocal 
electroretinography with signiﬁ  cant improvement in optical 
coherence tomography retinal thickness after intravitreal 
TA.64 Several studies showed a temporary decrease in 
retinal thickness corresponding to better visual acuity but it 
recurred within several months.65,63 Sorensen et al showed no 
improvement in visual acuity and foveal thickness in four 
patients after TA for pseudophakic CME. They therefore 
hypothesized a difference in the efﬁ  cacy of TA for CME 
depending on the etiology.50 Drs Jonas and Kamppeter 
published a case of persistent CME following penetrating 
keratoplasty effectively treated with intravitreal TA.68 While 
rare, recurrent postoperative CME resistant to conventional 
therapy can occur and intravitreal injections of TA may be 
helpful.
Complications of TA
Corticosteroids are notorious for many different adverse 
effects. The type and frequency of these effects is dependent 
mostly upon the route of administration. Ophthalmic 
consequences of local application of steroids include 
cataract progression and elevated intraocular pressure. Clinical Ophthalmology 2009:3 45
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When steroids are injected into the eye, many studies have 
shown a low risk of retinal detachment, vitreous hemorrhage 
and endophthalmitis, both infectious and noninfectious. 
Cataract development and progression are well known com-
plications of steroids, especially when injected intravitreally. 
Newly developed cataracts from intravitreal TA generally 
are posterior subcapsular in location. It is important to note 
that uveitis itself is a risk factor for the development of cata-
racts. Several studies have been published showing the inci-
dence of this to be anywhere from 29% to over 50% within 
1 year of followup.69,70,71 One hypothesis is that elevated 
intraocular pressure (IOP) plays a role in the development 
of cataracts as cataract progression was seen much higher 
in patients whose IOP was steroid responsive.72 Multiple 
studies have shown the increased incidence of elevated 
IOP following intravitreal TA administration.46,47,70,73,74,75 
One study comparing patients with and without uveitis 
treated with intravitreal TA showed the strongest risk factor 
for elevated IOP was the presence of uveitis.75 One study 
showed that eyes with an IOP above 15 mm Hg were more 
likely to developed steroid responsive elevated pressure.70 
The elevated IOP generally is controlled with temporary 
topical anti-glaucoma agents; however, surgical treatment to 
lower the IOP has been indicated in several studies.70,71,76,77,78 
Endophthalmitis following injection of TA can have an 
infectious or non-infectious etiology. Several studies have 
shown the incidence of infectious endophthalmitis to be 
around 0.5% and all types of endophthalmitis to be around 
1.1%.79,80,81 The term non-infectious endophthalmitis is 
reserved for true inﬂ  ammation that is thought to represent 
a immunologic response to TA or its preservative, benzyl 
alcohol.82,83,84,85,86 Another entity referred to as pseudo-
endophthalmitis describes TA crystals masquerading as 
inﬂ  ammatory cells.80,87 While there are several distinctive 
differences between these entities clinically, many times the 
clinical presentation overlaps. Non-infectious endophthal-
mitis generally manifests within a few days of treatment as 
a painless red eye with very prominent anterior chamber 
and vitreous reaction. Bacterial endophthalmitis generally 
presents up to 10 to 15 days after injection with severe pain, 
vision loss and prominent inﬂ  ammation both externally and 
internally. In addition to these risks of injection several 
other very rare complications have been reported including 
retinal detachment, vitreous hemorrhage, and conjunctival 
necrosis.70,88,89 Complications of intravitreal TA are rare but 
can be serious if they occur.
TA has been used for many decades in the treatment of 
ocular disease and its indications continue to expand. Direct 
treatment of ocular inﬂ  ammation with intravitreal injection 
limits systemic adverse effects. Because of its potent anti-
inﬂ  ammatory effects it can be used as an adjuvant in the 
treatment of recalcitrant uveitis and associated CME. It also 
shows promise as a treatment of uveitis in patients intolerant 
of other treatments. With a relatively low risk of adverse 
effects, it is regarded as safe in the treatment of uveitis and 
its associated macular edema.
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